{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-012243","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.593101+00:00","generated_at":"2026-05-16T10:26:17.910062+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvalent reports $1.4B cash, zidesamtinib PDUFA Sep 18, 2026; pipeline milestones","bullets":["Preliminary cash, cash equivalents and securities ~$1.4B as of Dec 31, 2025; runway into 2029.","FDA accepted NDA for zidesamtinib in TKI pre-treated ROS1+ NSCLC; PDUFA Sep 18, 2026.","NDA submission for neladalkib in TKI pre-treated ALK+ NSCLC planned for H1 2026.","Potential indication expansion submission for zidesamtinib in TKI-naïve ROS1+ NSCLC in H2 2026.","Progressing ALKAZAR Phase 3 (neladalkib, TKI-naïve ALK+) and HEROEX-1 Phase 1a/1b (NVL-330, HER2-altered NSCLC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-012243","json":"https://secwatch.observer/filing/0001193125-26-012243.json","markdown":"https://secwatch.observer/filing/0001193125-26-012243.md","text":"https://secwatch.observer/filing/0001193125-26-012243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526012243/0001193125-26-012243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526012243/nuvl-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:26:17.910062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}